Philip Barter

Professor Philip Barter is affiliated with the Central Clinical School at the University of Sydney, focusing on cardiovascular diseases, lipid metabolism, and metabolic syndrome. His research examines the role of high-density lipoproteins (HDL) in reducing inflammation, improving endothelial function, and mitigating diabetes-related complications.

• Key themes: Obesity, Diabetes, Cardiovascular Disease
• Email: philip.barter@sydney.edu.au
• Phone: +61 2 9550 3560

Research Interests include HDL biology, cholesteryl ester transfer protein (CETP) inhibition, and the interplay between lipid metabolism and inflammatory pathways. His work spans clinical trials, animal models, and metabolic biomarker analysis.

Publication Trends highlight HDL's therapeutic potential in diabetes, atherosclerosis, and vascular inflammation. Articles often analyze pharmacological agents like statins and CETP inhibitors, alongside epidemiological studies in diverse populations.

Collaborations involve institutions such as the Heart Research Institute and multi-center trials like the Mercy Study and FIELD trials. His work frequently addresses cardiovascular risk prediction and lipid-lowering therapies.